Immuron Limited (ASX:IMC)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Hyperimmune Products	7.29M	4.90M	1.80M	765.19K	145.78K
Hyperimmune Products Growth	48.63%	171.67%	135.85%	424.91%	-94.21%
Total	7.29M	4.90M	1.80M	765.19K	145.78K
Total Growth	48.63%	171.67%	135.85%	424.91%	-94.21%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
United States (US)	1.66M	1.08M	642.82K	501.23K	4.26K
United States (US) Growth	54.18%	67.33%	28.25%	11654.88%	-99.54%
Canada	378.71K	80.89K	1.20K	63.17K	101.64K
Canada Growth	368.19%	6635.05%	-98.10%	-37.85%	-66.34%
Australia	5.25M	3.75M	1.16M	200.79K	39.87K
Australia Growth	40.13%	222.77%	478.05%	403.58%	-96.91%
Total	7.29M	4.90M	1.80M	765.19K	145.78K
Total Growth	48.63%	171.67%	135.85%	424.91%	-94.21%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 19, 2026

Data Sources Report a data error